Literature DB >> 22391032

Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.

Garrett C Moraski1, Lowell D Markley, Mayland Chang, Sanghyun Cho, Scott G Franzblau, Chang Hwa Hwang, Helena Boshoff, Marvin J Miller.   

Abstract

Tuberculosis (TB) is a devastating disease resulting in a death every 20s. Thus, new drugs are urgently needed. Herein we report ten classes of compounds-oxazoline, oxazole, thiazoline, thiazole, pyrazole, pyridine, isoxazole, imidazo[1,2-a]pyridine, imidazo[1,2-a]pyrimidine and imidazo[1,2-c]pyrimidine-which have good (micromolar) to excellent (sub-micromolar) antitubercular potency. The 5,6-fused heteroaromatic compounds were the most potent with MIC's as low as <0.195 μM (9 and 11). Overall, the imidazo[1,2-a]pyridine class was determined to be most promising, with potency similar to isoniazid and PA-824 against replicating Mtb H(37)Rv, clinically relevant drug sensitive, multi- and extensively resistant Mtb strains as well as having good in vitro metabolic stability.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22391032      PMCID: PMC3304000          DOI: 10.1016/j.bmc.2012.02.025

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  18 in total

1.  Structure-activity relationship of new anti-tuberculosis agents derived from oxazoline and oxazole benzyl esters.

Authors:  Garrett C Moraski; Mayland Chang; Adriel Villegas-Estrada; Scott G Franzblau; Ute Möllmann; Marvin J Miller
Journal:  Eur J Med Chem       Date:  2010-01-14       Impact factor: 6.514

2.  Post Groebke-Blackburn multicomponent protocol: synthesis of new polyfunctional imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine derivatives as potential antimicrobial agents.

Authors:  Taleb H Al-Tel; Raed A Al-Qawasmeh
Journal:  Eur J Med Chem       Date:  2010-09-25       Impact factor: 6.514

3.  UTILIZTION OF THE SUZUKI COUPLING TO ENHANCE THE ANTITUBERCULOSIS ACTIVITY OF ARYL OXAZOLES.

Authors:  Garrett C Moraski; Scott G Franzblau; Marvin J Miller
Journal:  Heterocycles       Date:  2010-03-01       Impact factor: 0.831

Review 4.  Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis.

Authors:  James C Sacchettini; Eric J Rubin; Joel S Freundlich
Journal:  Nat Rev Microbiol       Date:  2008-01       Impact factor: 60.633

5.  Functionalized 3-amino-imidazo[1,2-a]pyridines: a novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors.

Authors:  Luke R Odell; Mikael T Nilsson; Johan Gising; Olof Lagerlund; Daniel Muthas; Anneli Nordqvist; Anders Karlén; Mats Larhed
Journal:  Bioorg Med Chem Lett       Date:  2009-06-14       Impact factor: 2.823

6.  Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity.

Authors:  Garrett C Moraski; Lowell D Markley; Philip A Hipskind; Helena Boshoff; Sanghyun Cho; Scott G Franzblau; Marvin J Miller
Journal:  ACS Med Chem Lett       Date:  2011-06-09       Impact factor: 4.345

7.  Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.

Authors:  Annamaria Lilienkampf; Marco Pieroni; Baojie Wan; Yuehong Wang; Scott G Franzblau; Alan P Kozikowski
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

8.  Iron transport-mediated antibacterial activity of and development of resistance to hydroxamate and catechol siderophore-carbacephalosporin conjugates.

Authors:  A A Minnick; J A McKee; E K Dolence; M J Miller
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

9.  A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy.

Authors:  Kevin Pethe; Patricia C Sequeira; Sanjay Agarwalla; Kyu Rhee; Kelli Kuhen; Wai Yee Phong; Viral Patel; David Beer; John R Walker; Jeyaraj Duraiswamy; Jan Jiricek; Thomas H Keller; Arnab Chatterjee; Mai Ping Tan; Manjunatha Ujjini; Srinivasa P S Rao; Luis Camacho; Pablo Bifani; Puiying A Mak; Ida Ma; S Whitney Barnes; Zhong Chen; David Plouffe; Pamela Thayalan; Seow Hwee Ng; Melvin Au; Boon Heng Lee; Bee Huat Tan; Sindhu Ravindran; Mahesh Nanjundappa; Xiuhua Lin; Anne Goh; Suresh B Lakshminarayana; Carolyn Shoen; Michael Cynamon; Barry Kreiswirth; Veronique Dartois; Eric C Peters; Richard Glynne; Sydney Brenner; Thomas Dick
Journal:  Nat Commun       Date:  2010-08-24       Impact factor: 14.919

10.  An inhibitor of exported Mycobacterium tuberculosis glutamine synthetase selectively blocks the growth of pathogenic mycobacteria in axenic culture and in human monocytes: extracellular proteins as potential novel drug targets.

Authors:  G Harth; M A Horwitz
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

View more
  18 in total

Review 1.  The tuberculosis drug discovery and development pipeline and emerging drug targets.

Authors:  Khisimuzi Mdluli; Takushi Kaneko; Anna Upton
Journal:  Cold Spring Harb Perspect Med       Date:  2015-01-29       Impact factor: 6.915

2.  Respiratory flexibility in response to inhibition of cytochrome C oxidase in Mycobacterium tuberculosis.

Authors:  Kriti Arora; Bernardo Ochoa-Montaño; Patricia S Tsang; Tom L Blundell; Stephanie S Dawes; Valerie Mizrahi; Tracy Bayliss; Claire J Mackenzie; Laura A T Cleghorn; Peter C Ray; Paul G Wyatt; Eugene Uh; Jinwoo Lee; Clifton E Barry; Helena I Boshoff
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

3.  Endless Resistance. Endless Antibiotics?

Authors:  Jed F Fisher; Shahriar Mobashery
Journal:  Medchemcomm       Date:  2015-11-03       Impact factor: 3.597

4.  Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates.

Authors:  Garrett C Moraski; Allen G Oliver; Lowell D Markley; Sanghyun Cho; Scott G Franzblau; Marvin J Miller
Journal:  Bioorg Med Chem Lett       Date:  2014-05-28       Impact factor: 2.823

5.  Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.

Authors:  Garrett C Moraski; Lowell D Markley; Jeffrey Cramer; Philip A Hipskind; Helena Boshoff; Mai Bailey; Torey Alling; Juliane Ollinger; Tanya Parish; Marvin J Miller
Journal:  ACS Med Chem Lett       Date:  2013-07-11       Impact factor: 4.345

6.  The pseudo-Michael reaction of 1-aryl-4,5-dihydro-1H-imidazol-2-amines with ethyl ethoxymethylenecyanoacetate.

Authors:  Agnieszka A Kaczor; Urszula Kijkowska-Murak; Kalevi Pihlaja; Jari Sinkkonen; Waldemar Wysocki; Zbigniew Karczmarzyk; Dariusz Matosiuk
Journal:  Monatsh Chem       Date:  2013-05-14       Impact factor: 1.451

7.  Putting Tuberculosis (TB) To Rest: Transformation of the Sleep Aid, Ambien, and "Anagrams" Generated Potent Antituberculosis Agents.

Authors:  Garrett C Moraski; Patricia A Miller; Mai Ann Bailey; Juliane Ollinger; Tanya Parish; Helena I Boshoff; Sanghyun Cho; Jeffery R Anderson; Surafel Mulugeta; Scott G Franzblau; Marvin J Miller
Journal:  ACS Infect Dis       Date:  2014-12-27       Impact factor: 5.084

8.  Synthesis, central nervous system activity, and structure-activity relationship of 1-aryl-6-benzyl-7-hydroxy-2,3-dihydroimidazo[1,2-a]pyrimidine-5(1H)-ones.

Authors:  Marzena Rządkowska; Elżbieta Szacoń; Agnieszka A Kaczor; Sylwia Fidecka; Ewa Kędzierska; Dariusz Matosiuk
Journal:  Med Chem Res       Date:  2014-03-27       Impact factor: 1.965

9.  In-silico Metabolome Target Analysis Towards PanC-based Antimycobacterial Agent Discovery.

Authors:  Baharak Khoshkholgh-Sima; Soroush Sardari; Jalal Izadi Mobarakeh; Ramezan Ali Khavari-Nejad
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

10.  A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis.

Authors:  Juliane Ollinger; Mai Ann Bailey; Garrett C Moraski; Allen Casey; Stephanie Florio; Torey Alling; Marvin J Miller; Tanya Parish
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.